Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies
Launched by CHILDREN HOSPITAL AND INSTITUTE OF CHILD HEALTH, LAHORE · Mar 25, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 6-15
- • Both genders
- • Diagnosed with scabies (as per operational definition)
- Exclusion Criteria:
- • Children with recurrent scabies on medical record
- • Known allergy to ivermectin or permethrin.
- • Widespread eczema or impetigo.
- • Liver dysfunction or renal failure
About Children Hospital And Institute Of Child Health, Lahore
The Children Hospital and Institute of Child Health in Lahore is a premier pediatric healthcare institution dedicated to advancing the health and well-being of children through innovative clinical research and high-quality medical care. As a leading sponsor of clinical trials, the institute emphasizes the importance of evidence-based practices and strives to enhance treatment options for various pediatric conditions. With a commitment to ethical standards and patient safety, the hospital collaborates with healthcare professionals, researchers, and academic institutions to foster groundbreaking studies that aim to improve pediatric outcomes and contribute to global health knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported